Please find enclosed herewith the submission regarding the launch of the latest products by the Company.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Royal Sense Limited has announced the launch of 7 new products in the pharmaceuticals category, effective 20th May, 2026. The product portfolio includes two antibiotic combinations (Stergiclav 625 and Smartyclav 625), two benzodiazepine-based psychiatric medications (Sterprax for anxiety and Stergipam MD for panic disorders), a pain management tablet (Stergicet with paracetamol and tramadol), a sleep aid (Sterpidem MD with zolpidem), and a digital blood pressure monitor device. All products are targeted at the domestic Indian market and will be sold as prescription-only medicines under Schedule H classification. The company has entered the CNS/psychiatric segment, pain management, and home healthcare device categories with this launch.
This launch expands Royal Sense's product portfolio into multiple high-growth pharmaceutical segments including antibiotics, CNS, and analgesics, plus a medical device. However, no revenue guidance, order values, or market share projections have been provided, making the near-term financial impact unclear for investors.